First Citizens Bank & Trust Co. reduced its stake in Philip Morris International by 12.3% during the third quarter, selling 6,120 shares and leaving it with 43,799 shares valued at approximately $7.1 million. Several other institutional investors also made moves: Legacy Investment Solutions and Traub Capital Management each initiated new positions worth about $25,000 in the second quarter; Marquette Asset Management expanded its position by 1,677.8% to 160 shares (roughly $26,000) in the third quarter; Briaud Financial Planning increased its stake by 266.7% to 165 shares (approximately $30,000) in the second quarter; and Estabrook Capital Management entered with a position valued at $30,000 in the same period. Institutional investors now own 78.63% of the company’s outstanding shares.

Philip Morris International declared a quarterly dividend of $1.47 per share, paid on January 14 to shareholders of record as of December 26. This dividend implies an annualized distribution of $5.88 per share and a yield of 3.4%, with a payout ratio of 106.52%. The elevated payout ratio reflects the company’s focus on returning cash to shareholders, even as it invests in reduced-risk product development.

Philip Morris presented scientific evidence to the FDA’s Tobacco Products Scientific Advisory Committee on January 22 as part of a modified-risk tobacco product application for its ZYN nicotine pouch. The company argued that switching completely from combustible cigarettes to ZYN reduces the risks of six smoking-related diseases—mouth cancer, lung cancer, heart disease, stroke, emphysema and chronic bronchitis. FDA briefing documents acknowledged that youth use of nicotine pouches remains low and concluded that the proposed claim is scientifically accurate. If approved, the label would allow the company to market ZYN as a reduced-risk alternative to adult smokers.

Eleven analysts currently rate Philip Morris shares as a Buy, while two assign a Hold rating, resulting in an average consensus of Moderate Buy. Recent research actions include overweight ratings from Morgan Stanley and Barclays, a buy reiteration from Goldman Sachs, and a downgrade to Hold from Wall Street Zen. Weiss Ratings has maintained a Buy (b) endorsement. The diversity of opinions reflects differing views on the company’s ability to navigate declining cigarette volumes while growing its smoke-free portfolio.